Advertisement

Lung Histopathology in Rheumatoid Arthritis

Chapter
Part of the Respiratory Medicine book series (RM)

Abstract

Rheumatoid arthritis can show a variety of pathologic patterns as either a manifestation of systemic autoimmune disease, as drug-induced pathology, or as infectious pathology. This chapter provides an overview of the possible histologic changes and gives an approach for aiding in the differentiation of these pathologic etiologies.

Keywords

Histopathology Interstitial pneumonia Infection Drug toxicity Rheumatoid arthritis 

References

  1. 1.
    Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. Br Med J. 1948;2(4583):816–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hart FD. Rheumatoid arthritis: extra-articular manifestations. Br Med J. 1969;3(5663):131–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bongartz T, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Travis WD, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sverzellati N, et al. American Thoracic Society-European Respiratory Society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographics. 2015;35(7):1849–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis. 1985;131(5):770–7.PubMedGoogle Scholar
  7. 7.
    Tanaka N, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232(1):81–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee HK, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127(6):2019–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshinouchi T, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int. 2005;26(2):121–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Assayag D, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270(2):583–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tansey D, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Fukuoka J, et al. Peribronchiolar metaplasia: a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease: clinicopathologic features of 15 cases. Am J Surg Pathol. 2005;29(7):948–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Kitamura A, et al. Rheumatoid arthritis with diffuse pulmonary rheumatoid nodules. Pathol Int. 2004;54(10):798–802.CrossRefPubMedGoogle Scholar
  14. 14.
    Tilstra JS, Lienesch DW. Rheumatoid nodules. Dermatol Clin. 2015;33(3):361–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Ishii H, et al. Desquamative interstitial pneumonia (DIP) in a patient with rheumatoid arthritis: is DIP associated with autoimmune disorders? Intern Med. 2009;48(10):827–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Cha SI, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Cipriani NA, et al. Pathologic quantification of connective tissue disease-associated versus idiopathic usual interstitial pneumonia. Arch Pathol Lab Med. 2012;136(10):1253–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Howling SJ, et al. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology. 1999;212(3):637–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Schlesinger C, et al. Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature. Ann Diagn Pathol. 1998;2(5):321–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Schlesinger C, Veeraraghavan S, Koss MN. Constrictive (obliterative) bronchiolitis. Curr Opin Pulm Med. 1998;4(5):288–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Chou CW, Chang SC. Pleuritis as a presenting manifestation of rheumatoid arthritis: diagnostic clues in pleural fluid cytology. Am J Med Sci. 2002;323(3):158–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Schneider F, et al. Pleuropulmonary pathology in patients with rheumatic disease. Arch Pathol Lab Med. 2012;136(10):1242–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Caulier M, et al. Sulfasalazine induced lupus in rheumatoid arthritis. J Rheumatol. 1994;21(4):750–1.PubMedGoogle Scholar
  24. 24.
    De Bandt M, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–51.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Travis WD, et al. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol. 1990;14(12):1112–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Torralbo A, et al. Alveolar hemorrhage associated with antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Chest. 1994;105(5):1590–2.CrossRefPubMedGoogle Scholar
  27. 27.
    Alarcon GS, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Sathi N, et al. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012;31(1):79–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Imokawa S, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15(2):373–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47(8):628–33.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kameda H, et al. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1585–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Blanchart K, et al. Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis. Minerva Anestesiol. 2014;80(1):119–20.PubMedGoogle Scholar
  33. 33.
    Oiwa H, et al. Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. Intern Med. 2014;53(16):1873–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kudrin A, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol. 2007;34(3):648–9.PubMedGoogle Scholar
  36. 36.
    Toussirot E, et al. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol. 2008;26(3):471–5.PubMedGoogle Scholar
  37. 37.
    Gifre L, et al. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2011;47(4):208–12.CrossRefPubMedGoogle Scholar
  38. 38.
    Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–26.CrossRefPubMedGoogle Scholar
  39. 39.
    Patkar NM, et al. Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol. 2008;20(3):320–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39(5):327–46.CrossRefPubMedGoogle Scholar
  41. 41.
    O’Reilly S, et al. Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole. Tuber Lung Dis. 1994;75(2):153–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Ohosone Y, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24(12):2299–303.PubMedGoogle Scholar
  43. 43.
    Mayordomo L, et al. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31(1):44–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Woyciechowsky TG, et al. Paracoccidioidomycosis induced by immunosuppressive drugs in a patient with rheumatoid arthritis and bone sarcoma: case report and review of the literature. Mycopathologia. 2011;172(1):77–81.CrossRefPubMedGoogle Scholar
  45. 45.
    Liao TL, et al. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case-control study in a TB endemic area. Sci Rep. 2016;6:29443.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Dublin S, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc. 2011;59(10):1899–907.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.University of CaliforniaSan FranciscoUSA

Personalised recommendations